APO Research
Talk to an analyst

APO RESEARCH · REPORT

Pharmaceutical & Biotechnology IP Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Pharmaceutical & Biotechnology IP Services Market Outlook and Growth Opportunities 2026

21 December 2025193 pages

Choose your research edition.

Industry ResearchPharmaceutical & Biotechnology IP Services Industry Research Report 2026132 pages · $2,950 USDIndustry Growth & TrendsGlobal Pharmaceutical & Biotechnology IP Services Industry Growth and Trends Forecast to 2032111 pages · $3,450 USDMarket StructureGlobal Pharmaceutical & Biotechnology IP Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032195 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Pharmaceutical & Biotechnology IP Services Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Pharmaceutical & Biotechnology IP Services Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

The global Pharmaceutical & Biotechnology IP Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Pharmaceutical & Biotechnology IP Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Pharmaceutical & Biotechnology IP Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Pharmaceutical & Biotechnology IP Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Pharmaceutical & Biotechnology IP Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Pharmaceutical & Biotechnology IP Services market include Finnegan, MBHB, Wolf Greenfield & Sacks, P.C., Kirkland & Ellis LLP, Sterne Kessler, Nelson Mullins Riley & Scarborough LLP, Pabst Patent Group, Excelon IP and Pharma Patents International, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Pharmaceutical & Biotechnology IP Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Pharmaceutical & Biotechnology IP Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Pharmaceutical & Biotechnology IP Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Pharmaceutical & Biotechnology IP Services market.

Pharmaceutical & Biotechnology IP Services Segment by Company

Finnegan

MBHB

Wolf Greenfield & Sacks, P.C.

Kirkland & Ellis LLP

Sterne Kessler

Nelson Mullins Riley & Scarborough LLP

Pabst Patent Group

Excelon IP

Pharma Patents International

J A Kemp

DLA Piper

Michael Best & Friedrich LLP

Troutman Pepper

Cooley LLP

Fish & Richardson

Pharmaceutical & Biotechnology IP Services Segment by Type

Patents

Copyrights

Trademarks

Others

Pharmaceutical & Biotechnology IP Services Segment by Application

Pharmaceutical Companies

Contract Research Organizations (CROs)

Others

Pharmaceutical & Biotechnology IP Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Pharmaceutical & Biotechnology IP Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Pharmaceutical & Biotechnology IP Services key companies, revenue, market share, and recent developments.

3. To split the Pharmaceutical & Biotechnology IP Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Pharmaceutical & Biotechnology IP Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Pharmaceutical & Biotechnology IP Services significant trends, drivers, influence factors in global and regions.

6. To analyze Pharmaceutical & Biotechnology IP Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmaceutical & Biotechnology IP Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Pharmaceutical & Biotechnology IP Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmaceutical & Biotechnology IP Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Pharmaceutical & Biotechnology IP Services industry.

Chapter 3: Detailed analysis of Pharmaceutical & Biotechnology IP Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Pharmaceutical & Biotechnology IP Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Pharmaceutical & Biotechnology IP Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Pharmaceutical & Biotechnology IP Services Industry Trends Table 2. Pharmaceutical & Biotechnology IP Services Industry Drivers Table 3. Pharmaceutical & Biotechnology IP Services Industry Opportunities and Challenges Table 4. Pharmaceutical & Biotechnology IP Services Industry Restraints Table 5. Global Pharmaceutical & Biotechnology IP Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Pharmaceutical & Biotechnology IP Services Revenue Share by Company (2021-2026) Table 7. Global Pharmaceutical & Biotechnology IP Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Pharmaceutical & Biotechnology IP Services Key Company Manufacturing Base & Headquarters Table 9. Global Pharmaceutical & Biotechnology IP Services Company, Product Type & Application Table 10. Global Pharmaceutical & Biotechnology IP Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Pharmaceutical & Biotechnology IP Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Patents Table 15. Significant Companies of Copyrights Table 16. Significant Companies of Trademarks Table 17. Significant Companies of Others Table 18. Global Pharmaceutical & Biotechnology IP Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global Pharmaceutical & Biotechnology IP Services Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global Pharmaceutical & Biotechnology IP Services Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Type (2021-2026) Table 22. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Pharmaceutical Companies Table 24. Significant Companies of Contract Research Organizations (CROs) Table 25. Significant Companies of Others Table 26. Global Pharmaceutical & Biotechnology IP Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 27. Global Pharmaceutical & Biotechnology IP Services Sales Value by Application (2021-2026) & (US$ Million) Table 28. Global Pharmaceutical & Biotechnology IP Services Sales Value by Application (2027-2032) & (US$ Million) Table 29. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Application (2021-2026) Table 30. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Application (2027-2032) Table 31. Global Pharmaceutical & Biotechnology IP Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 32. Global Pharmaceutical & Biotechnology IP Services Sales Value by Region (2021-2026) & (US$ Million) Table 33. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Region (2021-2026) Table 34. Global Pharmaceutical & Biotechnology IP Services Sales Value by Region (2027-2032) & (US$ Million) Table 35. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Region (2027-2032) Table 36. Global Pharmaceutical & Biotechnology IP Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 37. Global Pharmaceutical & Biotechnology IP Services Sales Value by Country (2021-2026) & (US$ Million) Table 38. Global Pharmaceutical & Biotechnology IP Services Sales Value Market Share by Country (2021-2026) Table 39. Global Pharmaceutical & Biotechnology IP Services Sales Value by Country (2027-2032) & (US$ Million) Table 40. Global Pharmaceutical & Biotechnology IP Services Sales Value Market Share by Country (2027-2032) Table 41. Finnegan Company Information Table 42. Finnegan Business Overview Table 43. Finnegan Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 44. Finnegan Pharmaceutical & Biotechnology IP Services Product Portfolio Table 45. Finnegan Recent Development Table 46. MBHB Company Information Table 47. MBHB Business Overview Table 48. MBHB Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 49. MBHB Pharmaceutical & Biotechnology IP Services Product Portfolio Table 50. MBHB Recent Development Table 51. Wolf Greenfield & Sacks, P.C. Company Information Table 52. Wolf Greenfield & Sacks, P.C. Business Overview Table 53. Wolf Greenfield & Sacks, P.C. Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 54. Wolf Greenfield & Sacks, P.C. Pharmaceutical & Biotechnology IP Services Product Portfolio Table 55. Wolf Greenfield & Sacks, P.C. Recent Development Table 56. Kirkland & Ellis LLP Company Information Table 57. Kirkland & Ellis LLP Business Overview Table 58. Kirkland & Ellis LLP Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 59. Kirkland & Ellis LLP Pharmaceutical & Biotechnology IP Services Product Portfolio Table 60. Kirkland & Ellis LLP Recent Development Table 61. Sterne Kessler Company Information Table 62. Sterne Kessler Business Overview Table 63. Sterne Kessler Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 64. Sterne Kessler Pharmaceutical & Biotechnology IP Services Product Portfolio Table 65. Sterne Kessler Recent Development Table 66. Nelson Mullins Riley & Scarborough LLP Company Information Table 67. Nelson Mullins Riley & Scarborough LLP Business Overview Table 68. Nelson Mullins Riley & Scarborough LLP Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Nelson Mullins Riley & Scarborough LLP Pharmaceutical & Biotechnology IP Services Product Portfolio Table 70. Nelson Mullins Riley & Scarborough LLP Recent Development Table 71. Pabst Patent Group Company Information Table 72. Pabst Patent Group Business Overview Table 73. Pabst Patent Group Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pabst Patent Group Pharmaceutical & Biotechnology IP Services Product Portfolio Table 75. Pabst Patent Group Recent Development Table 76. Excelon IP Company Information Table 77. Excelon IP Business Overview Table 78. Excelon IP Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Excelon IP Pharmaceutical & Biotechnology IP Services Product Portfolio Table 80. Excelon IP Recent Development Table 81. Pharma Patents International Company Information Table 82. Pharma Patents International Business Overview Table 83. Pharma Patents International Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. Pharma Patents International Pharmaceutical & Biotechnology IP Services Product Portfolio Table 85. Pharma Patents International Recent Development Table 86. J A Kemp Company Information Table 87. J A Kemp Business Overview Table 88. J A Kemp Pharmaceutical & Biotechnology IP Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. J A Kemp Pharmaceutical & Biotechnology IP Services Product Portfolio Table 90. J A Kemp Recent Development Table 91. DLA Piper Company Information Table 92. DLA Piper Business Overview Table 93. DLA Piper Pharmaceutical & Biotechnology IP Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 94. DLA Piper Pharmaceutical & Biotechnology IP Services Product Portfolio Table 95. DLA Piper Recent Development Table 96. Michael Best & Friedrich LLP Company Information Table 97. Michael Best & Friedrich LLP Business Overview Table 98. Michael Best & Friedrich LLP Pharmaceutical & Biotechnology IP Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 99. Michael Best & Friedrich LLP Pharmaceutical & Biotechnology IP Services Product Portfolio Table 100. Michael Best & Friedrich LLP Recent Development Table 101. Troutman Pepper Company Information Table 102. Troutman Pepper Business Overview Table 103. Troutman Pepper Pharmaceutical & Biotechnology IP Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 104. Troutman Pepper Pharmaceutical & Biotechnology IP Services Product Portfolio Table 105. Troutman Pepper Recent Development Table 106. Cooley LLP Company Information Table 107. Cooley LLP Business Overview Table 108. Cooley LLP Pharmaceutical & Biotechnology IP Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 109. Cooley LLP Pharmaceutical & Biotechnology IP Services Product Portfolio Table 110. Cooley LLP Recent Development Table 111. Fish & Richardson Company Information Table 112. Fish & Richardson Business Overview Table 113. Fish & Richardson Pharmaceutical & Biotechnology IP Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 114. Fish & Richardson Pharmaceutical & Biotechnology IP Services Product Portfolio Table 115. Fish & Richardson Recent Development Table 116. Research Programs/Design for This Report Table 117. Authors List of This Report Table 118. Secondary Sources Table 119. Primary Sources List of Figures Figure 1. Pharmaceutical & Biotechnology IP Services Product Image Figure 2. Global Pharmaceutical & Biotechnology IP Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Pharmaceutical & Biotechnology IP Services Market Size (2021-2032) & (US$ Million) Figure 4. Global Pharmaceutical & Biotechnology IP Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Patents Image Figure 8. Copyrights Image Figure 9. Trademarks Image Figure 10. Others Image Figure 11. Global Pharmaceutical & Biotechnology IP Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global Pharmaceutical & Biotechnology IP Services Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Type (2021-2032) Figure 14. Pharmaceutical Companies Image Figure 15. Contract Research Organizations (CROs) Image Figure 16. Others Image Figure 17. Global Pharmaceutical & Biotechnology IP Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 18. Global Pharmaceutical & Biotechnology IP Services Sales Value Share 2021 VS 2025 VS 2032 Figure 19. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Application (2021-2032) Figure 20. Global Pharmaceutical & Biotechnology IP Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 21. Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 22. North America Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032) & (US$ Million) Figure 23. North America Pharmaceutical & Biotechnology IP Services Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Europe Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032) & (US$ Million) Figure 25. Europe Pharmaceutical & Biotechnology IP Services Sales Value Share by Country (%), 2025 VS 2032 Figure 26. Asia-Pacific Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032) & (US$ Million) Figure 27. Asia-Pacific Pharmaceutical & Biotechnology IP Services Sales Value Share by Country (%), 2025 VS 2032 Figure 28. South America Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032) & (US$ Million) Figure 29. South America Pharmaceutical & Biotechnology IP Services Sales Value Share by Country (%), 2025 VS 2032 Figure 30. Middle East & Africa Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032) & (US$ Million) Figure 31. Middle East & Africa Pharmaceutical & Biotechnology IP Services Sales Value Share by Country (%), 2025 VS 2032 Figure 32. USA Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 33. USA Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 34. USA Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 35. Canada Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 36. Canada Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 37. Canada Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 38. Mexico Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 39. Mexico Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 40. Mexico Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 41. Germany Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. Germany Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. Germany Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. France Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. France Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. France Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. U.K. Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. U.K. Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. U.K. Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Italy Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Italy Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Italy Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. Spain Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. Spain Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. Spain Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. Russia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. Russia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. Russia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. China Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. China Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. China Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Japan Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Japan Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Japan Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. South Korea Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. South Korea Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. South Korea Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. India Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. India Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. India Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Australia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Australia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Australia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. Brazil Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. Brazil Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. Brazil Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Argentina Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Argentina Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Argentina Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Chile Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Chile Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Chile Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Colombia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Colombia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Colombia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Peru Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Peru Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Peru Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Israel Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Israel Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Israel Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. UAE Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. UAE Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. UAE Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Turkey Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Turkey Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Turkey Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Iran Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Iran Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Iran Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. Egypt Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. Egypt Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. Egypt Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Years Considered Figure 117. Research Process Figure 118. Key Executives Interviewed

Scope & coverage.

Types
  • Patents
  • Copyrights
  • Trademarks
  • Others
Applications
  • Pharmaceutical Companies
  • Contract Research Organizations (CROs)
  • Others
Companies covered
  • Finnegan
  • MBHB
  • Wolf Greenfield & Sacks, P.C.
  • Kirkland & Ellis LLP
  • Sterne Kessler
  • Nelson Mullins Riley & Scarborough LLP
  • Pabst Patent Group
  • Excelon IP
  • Pharma Patents International
  • J A Kemp
  • DLA Piper
  • Michael Best & Friedrich LLP
  • Troutman Pepper
  • Cooley LLP
  • Fish & Richardson

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Pharmaceutical & Biotechnology IP Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Pharmaceutical & Biotechnology IP Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Pharmaceutical & Biotechnology IP Services Market Dynamics
  1. 2.1 Pharmaceutical & Biotechnology IP Services Industry Trends
  2. 2.2 Pharmaceutical & Biotechnology IP Services Industry Drivers
  3. 2.3 Pharmaceutical & Biotechnology IP Services Industry Opportunities and Challenges
  4. 2.4 Pharmaceutical & Biotechnology IP Services Industry Restraints
3 Pharmaceutical & Biotechnology IP Services Market by Company
  1. 3.1 Global Pharmaceutical & Biotechnology IP Services Company Revenue Ranking in 2025
  2. 3.2 Global Pharmaceutical & Biotechnology IP Services Revenue by Company (2021-2026)
  3. 3.3 Global Pharmaceutical & Biotechnology IP Services Company Ranking (2024-2026)
  4. 3.4 Global Pharmaceutical & Biotechnology IP Services Company Manufacturing Base and Headquarters
  5. 3.5 Global Pharmaceutical & Biotechnology IP Services Company Product Type and Application
  6. 3.6 Global Pharmaceutical & Biotechnology IP Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Pharmaceutical & Biotechnology IP Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Pharmaceutical & Biotechnology IP Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Pharmaceutical & Biotechnology IP Services Market by Type
  1. 4.1 Pharmaceutical & Biotechnology IP Services Type Introduction
  2. 4.1.1 Patents
  3. 4.1.2 Copyrights
  4. 4.1.3 Trademarks
  5. 4.1.4 Others
  6. 4.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Type
  7. 4.2.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Type (2021-2032)
  9. 4.2.3 Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Type (2021-2032)
5 Pharmaceutical & Biotechnology IP Services Market by Application
  1. 5.1 Pharmaceutical & Biotechnology IP Services Application Introduction
  2. 5.1.1 Pharmaceutical Companies
  3. 5.1.2 Contract Research Organizations (CROs)
  4. 5.1.3 Others
  5. 5.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Application
  6. 5.2.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Application (2021-2032)
  8. 5.2.3 Global Pharmaceutical & Biotechnology IP Services Sales Value Share by Application (2021-2032)
6 Pharmaceutical & Biotechnology IP Services Regional Value Analysis
  1. 6.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032)
  7. 6.3.2 North America Pharmaceutical & Biotechnology IP Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032)
  10. 6.4.2 Europe Pharmaceutical & Biotechnology IP Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Pharmaceutical & Biotechnology IP Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032)
  16. 6.6.2 South America Pharmaceutical & Biotechnology IP Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Pharmaceutical & Biotechnology IP Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Pharmaceutical & Biotechnology IP Services Sales Value Share by Country, 2025 VS 2032
7 Pharmaceutical & Biotechnology IP Services Country-level Value Analysis
  1. 7.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global Pharmaceutical & Biotechnology IP Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global Pharmaceutical & Biotechnology IP Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Pharmaceutical & Biotechnology IP Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Pharmaceutical & Biotechnology IP Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Pharmaceutical & Biotechnology IP Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Finnegan
  2. 8.1.1 Finnegan Company Information
  3. 8.1.2 Finnegan Business Overview
  4. 8.1.3 Finnegan Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Finnegan Pharmaceutical & Biotechnology IP Services Product Portfolio
  6. 8.1.5 Finnegan Recent Developments
  7. 8.2 MBHB
  8. 8.2.1 MBHB Company Information
  9. 8.2.2 MBHB Business Overview
  10. 8.2.3 MBHB Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 MBHB Pharmaceutical & Biotechnology IP Services Product Portfolio
  12. 8.2.5 MBHB Recent Developments
  13. 8.3 Wolf Greenfield & Sacks, P.C.
  14. 8.3.1 Wolf Greenfield & Sacks, P.C. Company Information
  15. 8.3.2 Wolf Greenfield & Sacks, P.C. Business Overview
  16. 8.3.3 Wolf Greenfield & Sacks, P.C. Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Wolf Greenfield & Sacks, P.C. Pharmaceutical & Biotechnology IP Services Product Portfolio
  18. 8.3.5 Wolf Greenfield & Sacks, P.C. Recent Developments
  19. 8.4 Kirkland & Ellis LLP
  20. 8.4.1 Kirkland & Ellis LLP Company Information
  21. 8.4.2 Kirkland & Ellis LLP Business Overview
  22. 8.4.3 Kirkland & Ellis LLP Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Kirkland & Ellis LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
  24. 8.4.5 Kirkland & Ellis LLP Recent Developments
  25. 8.5 Sterne Kessler
  26. 8.5.1 Sterne Kessler Company Information
  27. 8.5.2 Sterne Kessler Business Overview
  28. 8.5.3 Sterne Kessler Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Sterne Kessler Pharmaceutical & Biotechnology IP Services Product Portfolio
  30. 8.5.5 Sterne Kessler Recent Developments
  31. 8.6 Nelson Mullins Riley & Scarborough LLP
  32. 8.6.1 Nelson Mullins Riley & Scarborough LLP Company Information
  33. 8.6.2 Nelson Mullins Riley & Scarborough LLP Business Overview
  34. 8.6.3 Nelson Mullins Riley & Scarborough LLP Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Nelson Mullins Riley & Scarborough LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
  36. 8.6.5 Nelson Mullins Riley & Scarborough LLP Recent Developments
  37. 8.7 Pabst Patent Group
  38. 8.7.1 Pabst Patent Group Company Information
  39. 8.7.2 Pabst Patent Group Business Overview
  40. 8.7.3 Pabst Patent Group Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Pabst Patent Group Pharmaceutical & Biotechnology IP Services Product Portfolio
  42. 8.7.5 Pabst Patent Group Recent Developments
  43. 8.8 Excelon IP
  44. 8.8.1 Excelon IP Company Information
  45. 8.8.2 Excelon IP Business Overview
  46. 8.8.3 Excelon IP Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Excelon IP Pharmaceutical & Biotechnology IP Services Product Portfolio
  48. 8.8.5 Excelon IP Recent Developments
  49. 8.9 Pharma Patents International
  50. 8.9.1 Pharma Patents International Company Information
  51. 8.9.2 Pharma Patents International Business Overview
  52. 8.9.3 Pharma Patents International Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Pharma Patents International Pharmaceutical & Biotechnology IP Services Product Portfolio
  54. 8.9.5 Pharma Patents International Recent Developments
  55. 8.10 J A Kemp
  56. 8.10.1 J A Kemp Company Information
  57. 8.10.2 J A Kemp Business Overview
  58. 8.10.3 J A Kemp Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 J A Kemp Pharmaceutical & Biotechnology IP Services Product Portfolio
  60. 8.10.5 J A Kemp Recent Developments
  61. 8.11 DLA Piper
  62. 8.11.1 DLA Piper Company Information
  63. 8.11.2 DLA Piper Business Overview
  64. 8.11.3 DLA Piper Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 DLA Piper Pharmaceutical & Biotechnology IP Services Product Portfolio
  66. 8.11.5 DLA Piper Recent Developments
  67. 8.12 Michael Best & Friedrich LLP
  68. 8.12.1 Michael Best & Friedrich LLP Company Information
  69. 8.12.2 Michael Best & Friedrich LLP Business Overview
  70. 8.12.3 Michael Best & Friedrich LLP Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Michael Best & Friedrich LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
  72. 8.12.5 Michael Best & Friedrich LLP Recent Developments
  73. 8.13 Troutman Pepper
  74. 8.13.1 Troutman Pepper Company Information
  75. 8.13.2 Troutman Pepper Business Overview
  76. 8.13.3 Troutman Pepper Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Troutman Pepper Pharmaceutical & Biotechnology IP Services Product Portfolio
  78. 8.13.5 Troutman Pepper Recent Developments
  79. 8.14 Cooley LLP
  80. 8.14.1 Cooley LLP Company Information
  81. 8.14.2 Cooley LLP Business Overview
  82. 8.14.3 Cooley LLP Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Cooley LLP Pharmaceutical & Biotechnology IP Services Product Portfolio
  84. 8.14.5 Cooley LLP Recent Developments
  85. 8.15 Fish & Richardson
  86. 8.15.1 Fish & Richardson Company Information
  87. 8.15.2 Fish & Richardson Business Overview
  88. 8.15.3 Fish & Richardson Pharmaceutical & Biotechnology IP Services Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Fish & Richardson Pharmaceutical & Biotechnology IP Services Product Portfolio
  90. 8.15.5 Fish & Richardson Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst